731 related articles for article (PubMed ID: 26438511)
1. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.
Garg M; Nagata Y; Kanojia D; Mayakonda A; Yoshida K; Haridas Keloth S; Zang ZJ; Okuno Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ding LW; Alpermann T; Sun QY; Lin DC; Chien W; Madan V; Liu LZ; Tan KT; Sampath A; Venkatesan S; Inokuchi K; Wakita S; Yamaguchi H; Chng WJ; Kham SK; Yeoh AE; Sanada M; Schiller J; Kreuzer KA; Kornblau SM; Kantarjian HM; Haferlach T; Lill M; Kuo MC; Shih LY; Blau IW; Blau O; Yang H; Ogawa S; Koeffler HP
Blood; 2015 Nov; 126(22):2491-501. PubMed ID: 26438511
[TBL] [Abstract][Full Text] [Related]
2. Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin.
Ottone T; Zaza S; Divona M; Hasan SK; Lavorgna S; Laterza S; Cicconi L; Panetta P; Di Giandomenico J; Cittadini M; Ciardi C; Montefusco E; Franchi A; Annino L; Venditti A; Amadori S; Lo-Coco F
Br J Haematol; 2013 May; 161(4):533-40. PubMed ID: 23480665
[TBL] [Abstract][Full Text] [Related]
3. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
4. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.
Nazha A; Cortes J; Faderl S; Pierce S; Daver N; Kadia T; Borthakur G; Luthra R; Kantarjian H; Ravandi F
Haematologica; 2012 Aug; 97(8):1242-5. PubMed ID: 22532519
[TBL] [Abstract][Full Text] [Related]
5. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
7. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology.
McCormick SR; McCormick MJ; Grutkoski PS; Ducker GS; Banerji N; Higgins RR; Mendiola JR; Reinartz JJ
Arch Pathol Lab Med; 2010 Aug; 134(8):1143-51. PubMed ID: 20670134
[TBL] [Abstract][Full Text] [Related]
8. Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.
Cesano A; Putta S; Rosen DB; Cohen AC; Gayko U; Mathi K; Woronicz J; Hawtin RE; Cripe L; Sun Z; Tallman MS; Paietta E
PLoS One; 2013; 8(2):e56714. PubMed ID: 23431389
[TBL] [Abstract][Full Text] [Related]
9. Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.
Zuffa E; Franchini E; Papayannidis C; Baldazzi C; Simonetti G; Testoni N; Abbenante MC; Paolini S; Sartor C; Parisi S; Marconi G; Cattina F; Bochicchio MT; Venturi C; Ottaviani E; Cavo M; Martinelli G
Oncotarget; 2015 Oct; 6(31):31284-94. PubMed ID: 26384303
[TBL] [Abstract][Full Text] [Related]
10. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
[TBL] [Abstract][Full Text] [Related]
11. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
12. Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.
Buelow DR; Pounds SB; Wang YD; Shi L; Li Y; Finkelstein D; Shurtleff S; Neale G; Inaba H; Ribeiro RC; Palumbo R; Garrison D; Orwick SJ; Blachly JS; Kroll K; Byrd JC; Gruber TA; Rubnitz JE; Baker SD
Clin Transl Sci; 2019 Nov; 12(6):641-647. PubMed ID: 31350825
[TBL] [Abstract][Full Text] [Related]
13. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
[TBL] [Abstract][Full Text] [Related]
15. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
16. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.
Schwartz GW; Manning B; Zhou Y; Velu P; Bigdeli A; Astles R; Lehman AW; Morrissette JJD; Perl AE; Li M; Carroll M; Faryabi RB
Clin Cancer Res; 2019 Jan; 25(2):573-583. PubMed ID: 30181385
[TBL] [Abstract][Full Text] [Related]
17. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
18. Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study.
Ebian HF; Elshorbagy S; Mohamed H; Embaby A; Khamis T; Sameh R; Sabbah NA; Hussein S
Cancer Biomark; 2021; 32(3):379-389. PubMed ID: 34487021
[TBL] [Abstract][Full Text] [Related]
19. High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication.
Gourdin TS; Zou Y; Ning Y; Emadi A; Duong VH; Tidwell ML; Chen C; Rassool FV; Baer MR
Cancer Genet; 2014; 207(10-12):467-73. PubMed ID: 25441683
[TBL] [Abstract][Full Text] [Related]
20. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock LK; Dolnik A; Cocciardi S; Sträng E; Theis F; Jahn N; Panina E; Blätte TJ; Herzig J; Skambraks S; Rücker FG; Gaidzik VI; Paschka P; Fiedler W; Salih HR; Wulf G; Schroeder T; Lübbert M; Schlenk RF; Thol F; Heuser M; Larson RA; Ganser A; Stunnenberg HG; Minucci S; Stone RM; Bloomfield CD; Döhner H; Döhner K; Bullinger L
Blood; 2021 Jun; 137(22):3093-3104. PubMed ID: 33598693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
